anthera pharmaceuticals inc (ANTH) Key Developments
Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus
Feb 10 15
Anthera Pharmaceuticals, Inc. announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the 24 week time point. Enrollment in the trial is projected to conclude in mid-2015. Prior to the interim analysis and in response to recent input from the Company's Scientific Advisory Board following the publication of clinical data from other Lupus studies with BAFF inhibitors, the Company modified the primary endpoint of CHABLIS-SC1 from SRI-8 response to SRI-6 response, which was previously a secondary endpoint of the study.
Anthera Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
Feb 10 15
Anthera Pharmaceuticals announced that the company has received formal notification from the Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders' equity or maintaining a market value of $50,000,000 or greater for ten consecutive business days. Nasdaq has determined that Anthera has maintained market value of at least $50,000,000 for the last ten consecutive business days and as such, the Company has met alternative listing requirements for continued listing.
Anthera Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM
Jan 12 15
Anthera Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Paul F. Truex, Chief Executive Officer, President and Director.
Anthera Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015
Jan 9 15
Anthera Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.
Anthera Pharmaceuticals Announces Appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer
Jan 7 15
Anthera Pharmaceuticals, Inc. announced the appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer. Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014.